Retinal Vascular Disease · Posterior Segment Series
One blocked vein.
Two very different
emergencies.
A retinal vein occlusion is not one disease. It is a family of vascular events that share a mechanism — a vein compressed and clotted where it crosses a stiffer vessel — but differ sharply in how much retina goes without drainage and what that does to vision. Here is the anatomy, the ischemia math that decides treatment, and the evidence behind modern anti-VEGF care.
vascular disease
BRVO occurs than CRVO
"ischemic" CRVO
Section 01 — One Mechanism, Two Territories
Same kind of clot.
Completely different
amount of retina.
Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy, and it is really two conditions wearing one name. Branch retinal vein occlusion (BRVO) blocks one of the smaller veins draining a sector of the retina. Central retinal vein occlusion (CRVO) blocks the single trunk vein that every other vein empties into, on its way out of the eye. Same underlying process — venous compression at a crossing point, followed by turbulent flow and thrombosis — applied to two very different amounts of retinal territory.
That territory difference is why the two are not interchangeable diagnoses with interchangeable urgency. A BRVO affects the wedge of retina drained by one branch vein; vision loss is usually partial and often improves as the acute hemorrhage and edema settle. A CRVO affects the entire retina at once, because every branch vein empties through the same blocked trunk. Population-based studies estimate BRVO occurs roughly four times more often than CRVO, but CRVO carries the greater risk of severe, permanent vision loss and the feared complication covered later in this guide: neovascular glaucoma.
RVO happens when a retinal vein is compressed and clots where it crosses a stiffer artery (branch occlusion) or where it exits the eye through the rigid lamina cribrosa alongside the central retinal artery (central occlusion). Blood keeps arriving but cannot drain, so the affected veins engorge, capillaries leak or close, and the retina develops hemorrhage, swelling and, in severe cases, zones starved of blood flow. Vision loss is driven mainly by macular edema in both types, and by retinal ischemia specifically in central occlusion — ischemia severe enough to trigger abnormal new vessel growth and, in the worst cases, a dangerous rise in eye pressure.
Section 02 — Interactive
Where the block sits
decides how much retina
backs up.
Toggle between a branch occlusion and a central occlusion below. Watch which part of the venous tree stops draining — one wedge of retina, or all of it at once. This is a simplified schematic of retinal venous drainage, not a fundus photograph or diagnostic tool.
In the branch view, only the vessel downstream of the blockage backs up — the other three branches keep draining into the disc unaffected, which is exactly why BRVO produces a sector-shaped area of hemorrhage and edema rather than a whole-retina picture. In the central view, the blockage sits on the trunk itself, after every branch has already joined it, so all four branches back up simultaneously. That single anatomical fact — one trunk versus four independent branches — is most of the reason CRVO is the more dangerous diagnosis of the two.
Section 03 — Classification
Ischemic or not
is the question that
decides everything else.
Within both BRVO and CRVO, the single most important clinical split is whether the occlusion is ischemic or non-ischemic (also called perfused). It is not a cosmetic distinction — it determines follow-up frequency, the risk of neovascular complications, and how aggressively a surgeon watches the angle and the iris.
The historic reference point is the Central Vein Occlusion Study (CVOS), which defined ischemic CRVO by the extent of capillary non-perfusion visible on fluorescein angiography — conventionally, ten or more disc areas of non-perfused retina. Below that threshold, an occlusion is classified as non-ischemic. The distinction matters because it is not fixed at presentation: a meaningful proportion of eyes that start out non-ischemic convert to ischemic over the following months to a few years, which is why CVOS-era guidance calls for continued angiographic and clinical monitoring rather than a single baseline judgment.
| Feature | Non-ischemic (perfused) | Ischemic |
|---|---|---|
| Capillary non-perfusion | Below the ischemic threshold | ≥10 disc areas on fluorescein angiography (CVOS criterion, CRVO) |
| Visual acuity at presentation | Often better preserved | Frequently poor, reflecting the extent of retinal ischemia |
| Relative afferent pupillary defect | Absent or mild | Often present — a clinical clue to ischemic burden |
| Neovascularization risk | Low | Materially higher — the driver of neovascular glaucoma risk |
| Course | Can convert to ischemic over time — requires ongoing monitoring | Established; monitored for anterior segment neovascularization |
The same ischemic/non-ischemic split applies to BRVO, though the neovascular risk is lower overall because a branch occlusion, by definition, ischemic or not, involves only a sector of retina rather than the whole posterior pole.
Section 04 — The Evidence
From laser
to anti-VEGF:
how treatment changed.
RVO treatment has gone through a genuine paradigm shift, and the trial history is unusually well documented because both major treatment eras were tested in large, randomized, multicenter studies rather than adopted on the strength of small case series.
Illustrative visualisation of the direction reported across the pivotal trials cited below — not pooled effect sizes or a head-to-head ranking.
Grid and focal laser photocoagulation was the original evidence-based treatment for BRVO macular edema, established by the Branch Vein Occlusion Study (BVOS) in 1984, and panretinal photocoagulation for neovascularization was established by the Central Vein Occlusion Study through the 1990s — that laser standard for treating established neovascularization has not changed. What changed was macular edema treatment. The BRAVO trial (ranibizumab for BRVO) and CRUISE trial (ranibizumab for CRVO), both published in 2010, demonstrated that monthly intravitreal anti-VEGF injections produced meaningfully greater visual acuity gains than laser or sham treatment over six months. Aflibercept followed with its own pivotal evidence in CRVO through the GALILEO and COPERNICUS trials, and in BRVO through the VIBRANT trial. In parallel, the GENEVA study established the dexamethasone intravitreal implant as an effective alternative for RVO-related macular edema, particularly relevant in eyes that are pseudophakic or that respond poorly to anti-VEGF.
ischemic CRVO (CVOS)
common BRVO is than CRVO
"90-day glaucoma" after ischemic CRVO
Section 05 — Who Gets It
The risk factors
read like a
cardiovascular checklist.
RVO is, in large part, a vascular disease that happens to present in the eye. The dominant risk factors overlap heavily with the systemic conditions a cardiologist screens for, which is part of why an RVO diagnosis often prompts a referral back to a physician for blood pressure, glucose and lipid evaluation rather than staying purely an ophthalmology problem.
| Risk factor | Relevance |
|---|---|
| Systemic hypertension | The single most consistently identified risk factor for both BRVO and CRVO |
| Atherosclerotic cardiovascular disease | Stiffens the arteries that compress veins at crossing points and at the lamina cribrosa |
| Diabetes mellitus | Independent risk factor; also complicates the retinal vascular picture if diabetic retinopathy coexists |
| Elevated intraocular pressure / glaucoma | Raises risk, particularly for BRVO; open-angle glaucoma is a recognized association |
| Hyperlipidemia | Contributes to the same atherosclerotic process driving arteriovenous compression |
| Hypercoagulable states | More relevant in RVO presenting at a younger age without the usual vascular risk profile |
| Age over 50 | Incidence rises steadily with age, paralleling the rise in vascular risk factors |
None of these factors is unique to the eye, which is the point: an RVO diagnosis is as much a signal about systemic vascular health as it is a retinal event, and management appropriately includes addressing blood pressure and metabolic risk alongside whatever intraocular treatment the macular edema or ischemia requires.
Section 06 — The Complication That Changes Everything
When ischemia
turns into
neovascular glaucoma.
The complication that makes ischemic CRVO an emergency rather than a routine follow-up is neovascular glaucoma. It is the reason ischemic and non-ischemic classification is not academic — it is the variable that decides how closely an eye needs to be watched in the months after diagnosis.
A large area of ischemic retina releases vascular endothelial growth factor (VEGF) as a response to oxygen starvation. In most tissues that drives helpful new blood vessel growth; in the eye, when those signals reach the iris and the anterior chamber angle, they trigger fragile, abnormal vessels (rubeosis iridis) that can physically block the eye's normal fluid drainage pathway. The result is a rapid, often severe rise in intraocular pressure that is difficult to control with drops alone — historically nicknamed "90-day glaucoma" because it classically appeared within about three months of an ischemic CRVO, though it can occur earlier or later.
Section 07 — Where the Decision Actually Gets Made
Same symptom,
different urgency —
an illustrative comparison.
Two patients can describe the same complaint — sudden, painless blurring in one eye — and be on entirely different clinical tracks once the fundus exam and angiography sort out which type of occlusion, and which ischemic status, they actually have.
A composite BRVO presentation: painless blurring affecting the upper or lower half of vision in one eye, corresponding to hemorrhage and edema along one branch vein, often at a visible arteriovenous crossing on exam. Visual acuity may be only mildly reduced if the occlusion spares the fovea. Management centers on monitoring, treating macular edema if it involves the center of vision, and addressing systemic risk factors — the prognosis for at least partial visual recovery is generally favorable.
A composite ischemic CRVO presentation: sudden, more uniform, and often more severe blurring across the entire visual field of one eye, with diffuse hemorrhage in all four quadrants of the retina on exam (the classic "blood and thunder" fundus appearance) and a relative afferent pupillary defect suggesting significant ischemia. This eye needs angiography to confirm ischemic status and a short-interval follow-up schedule specifically to watch for anterior segment neovascularization, independent of whatever happens with the macular edema itself.
The point is not that one occlusion is "worse" as a category — both merit prompt ophthalmic evaluation for any sudden visual change — but that the same first symptom can sit on either a watchful, largely reassuring path or an urgent, closely monitored one, and the fundus exam plus angiography is what tells them apart, not the symptom alone.
Section 08 — FAQ
Frequently asked questions
about retinal vein occlusion.
Retinal vein occlusion (RVO) is a blockage, usually a thrombus, forming in one of the veins that drain blood out of the retina. Blood keeps arriving through the retinal arteries but cannot leave normally, so pressure builds up behind the blockage, veins become engorged and tortuous, and the retina develops hemorrhages, swelling and, in more severe cases, areas starved of blood flow. It is the second most common retinal vascular disease after diabetic retinopathy.
The difference is where the blockage sits. Branch retinal vein occlusion (BRVO) blocks one of the smaller branch veins, typically at a point where it crosses under a stiffer retinal artery, so only the section of retina that branch drains is affected. Central retinal vein occlusion (CRVO) blocks the single central retinal vein at or near the optic nerve, at the narrow scleral canal called the lamina cribrosa, affecting the entire retina at once. BRVO is reported to occur roughly four times more often than CRVO in population-based studies, and CRVO is generally the more visually threatening of the two because it involves the whole retina rather than one sector.
In BRVO, the vein and an overlying artery share a common connective-tissue sheath at crossing points; a thickened, more rigid artery (from atherosclerosis or chronic hypertension) can compress the vein at that shared sheath, disturbing blood flow enough to trigger clot formation. In CRVO, the mechanism is similar but occurs where the vein exits the eye through the lamina cribrosa alongside the central retinal artery, inside a shared, rigid scleral canal. The dominant systemic risk factors for both are hypertension, atherosclerotic disease, diabetes, and elevated intraocular pressure or glaucoma; age over 50 and hypercoagulable states also raise risk.
The leading cause of vision loss in both BRVO and CRVO is macular edema — fluid leaking into the central retina because the congested veins and damaged capillaries can no longer hold it in. Macular edema is treatable, most often with intravitreal anti-VEGF injections or a corticosteroid implant, both of which reduce leakage and can recover meaningful vision, though outcomes depend heavily on how much macular ischemia and how long the edema has been present before treatment starts.
When a large area of retina is starved of blood flow, as happens in ischemic CRVO, the retina releases VEGF signals that can trigger abnormal new blood vessels to grow on the iris and in the eye's drainage angle. These fragile vessels can block normal fluid outflow and cause a severe, often difficult-to-control form of glaucoma historically nicknamed "90-day glaucoma" for how soon after an ischemic CRVO it can appear. It is treated with panretinal laser photocoagulation to reduce the ischemic drive, anti-VEGF injections, and, if pressure remains uncontrolled, glaucoma surgery.
Intravitreal anti-VEGF injections (ranibizumab, aflibercept, and off-label bevacizumab) are now first-line for the macular edema of both BRVO and CRVO, supported by pivotal trials including BRAVO, CRUISE, GALILEO and COPERNICUS. An intravitreal corticosteroid implant is a well-evidenced alternative, particularly in eyes that respond poorly to anti-VEGF or are already pseudophakic, based on the GENEVA trial. Grid or focal laser, once the standard for BRVO macular edema under the Branch Vein Occlusion Study, is now mostly reserved for cases not resolving with injections. Panretinal photocoagulation remains the standard response once retinal or iris neovascularization develops.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Retinal Vascular Disease · Posterior Segment Series
One blocked vein.
Two very different
emergencies.
A retinal vein occlusion is not one disease. It is a family of vascular events that share a mechanism — a vein compressed and clotted where it crosses a stiffer vessel — but differ sharply in how much retina goes without drainage and what that does to vision. Here is the anatomy, the ischemia math that decides treatment, and the evidence behind modern anti-VEGF care.
vascular disease
BRVO occurs than CRVO
"ischemic" CRVO
Section 01 — One Mechanism, Two Territories
Same kind of clot.
Completely different
amount of retina.
Retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy, and it is really two conditions wearing one name. Branch retinal vein occlusion (BRVO) blocks one of the smaller veins draining a sector of the retina. Central retinal vein occlusion (CRVO) blocks the single trunk vein that every other vein empties into, on its way out of the eye. Same underlying process — venous compression at a crossing point, followed by turbulent flow and thrombosis — applied to two very different amounts of retinal territory.
That territory difference is why the two are not interchangeable diagnoses with interchangeable urgency. A BRVO affects the wedge of retina drained by one branch vein; vision loss is usually partial and often improves as the acute hemorrhage and edema settle. A CRVO affects the entire retina at once, because every branch vein empties through the same blocked trunk. Population-based studies estimate BRVO occurs roughly four times more often than CRVO, but CRVO carries the greater risk of severe, permanent vision loss and the feared complication covered later in this guide: neovascular glaucoma.
RVO happens when a retinal vein is compressed and clots where it crosses a stiffer artery (branch occlusion) or where it exits the eye through the rigid lamina cribrosa alongside the central retinal artery (central occlusion). Blood keeps arriving but cannot drain, so the affected veins engorge, capillaries leak or close, and the retina develops hemorrhage, swelling and, in severe cases, zones starved of blood flow. Vision loss is driven mainly by macular edema in both types, and by retinal ischemia specifically in central occlusion — ischemia severe enough to trigger abnormal new vessel growth and, in the worst cases, a dangerous rise in eye pressure.
Section 02 — Interactive
Where the block sits
decides how much retina
backs up.
Toggle between a branch occlusion and a central occlusion below. Watch which part of the venous tree stops draining — one wedge of retina, or all of it at once. This is a simplified schematic of retinal venous drainage, not a fundus photograph or diagnostic tool.
In the branch view, only the vessel downstream of the blockage backs up — the other three branches keep draining into the disc unaffected, which is exactly why BRVO produces a sector-shaped area of hemorrhage and edema rather than a whole-retina picture. In the central view, the blockage sits on the trunk itself, after every branch has already joined it, so all four branches back up simultaneously. That single anatomical fact — one trunk versus four independent branches — is most of the reason CRVO is the more dangerous diagnosis of the two.
Section 03 — Classification
Ischemic or not
is the question that
decides everything else.
Within both BRVO and CRVO, the single most important clinical split is whether the occlusion is ischemic or non-ischemic (also called perfused). It is not a cosmetic distinction — it determines follow-up frequency, the risk of neovascular complications, and how aggressively a surgeon watches the angle and the iris.
The historic reference point is the Central Vein Occlusion Study (CVOS), which defined ischemic CRVO by the extent of capillary non-perfusion visible on fluorescein angiography — conventionally, ten or more disc areas of non-perfused retina. Below that threshold, an occlusion is classified as non-ischemic. The distinction matters because it is not fixed at presentation: a meaningful proportion of eyes that start out non-ischemic convert to ischemic over the following months to a few years, which is why CVOS-era guidance calls for continued angiographic and clinical monitoring rather than a single baseline judgment.
| Feature | Non-ischemic (perfused) | Ischemic |
|---|---|---|
| Capillary non-perfusion | Below the ischemic threshold | ≥10 disc areas on fluorescein angiography (CVOS criterion, CRVO) |
| Visual acuity at presentation | Often better preserved | Frequently poor, reflecting the extent of retinal ischemia |
| Relative afferent pupillary defect | Absent or mild | Often present — a clinical clue to ischemic burden |
| Neovascularization risk | Low | Materially higher — the driver of neovascular glaucoma risk |
| Course | Can convert to ischemic over time — requires ongoing monitoring | Established; monitored for anterior segment neovascularization |
The same ischemic/non-ischemic split applies to BRVO, though the neovascular risk is lower overall because a branch occlusion, by definition, ischemic or not, involves only a sector of retina rather than the whole posterior pole.
Section 04 — The Evidence
From laser
to anti-VEGF:
how treatment changed.
RVO treatment has gone through a genuine paradigm shift, and the trial history is unusually well documented because both major treatment eras were tested in large, randomized, multicenter studies rather than adopted on the strength of small case series.
Illustrative visualisation of the direction reported across the pivotal trials cited below — not pooled effect sizes or a head-to-head ranking.
Grid and focal laser photocoagulation was the original evidence-based treatment for BRVO macular edema, established by the Branch Vein Occlusion Study (BVOS) in 1984, and panretinal photocoagulation for neovascularization was established by the Central Vein Occlusion Study through the 1990s — that laser standard for treating established neovascularization has not changed. What changed was macular edema treatment. The BRAVO trial (ranibizumab for BRVO) and CRUISE trial (ranibizumab for CRVO), both published in 2010, demonstrated that monthly intravitreal anti-VEGF injections produced meaningfully greater visual acuity gains than laser or sham treatment over six months. Aflibercept followed with its own pivotal evidence in CRVO through the GALILEO and COPERNICUS trials, and in BRVO through the VIBRANT trial. In parallel, the GENEVA study established the dexamethasone intravitreal implant as an effective alternative for RVO-related macular edema, particularly relevant in eyes that are pseudophakic or that respond poorly to anti-VEGF.
ischemic CRVO (CVOS)
common BRVO is than CRVO
"90-day glaucoma" after ischemic CRVO
Section 05 — Who Gets It
The risk factors
read like a
cardiovascular checklist.
RVO is, in large part, a vascular disease that happens to present in the eye. The dominant risk factors overlap heavily with the systemic conditions a cardiologist screens for, which is part of why an RVO diagnosis often prompts a referral back to a physician for blood pressure, glucose and lipid evaluation rather than staying purely an ophthalmology problem.
| Risk factor | Relevance |
|---|---|
| Systemic hypertension | The single most consistently identified risk factor for both BRVO and CRVO |
| Atherosclerotic cardiovascular disease | Stiffens the arteries that compress veins at crossing points and at the lamina cribrosa |
| Diabetes mellitus | Independent risk factor; also complicates the retinal vascular picture if diabetic retinopathy coexists |
| Elevated intraocular pressure / glaucoma | Raises risk, particularly for BRVO; open-angle glaucoma is a recognized association |
| Hyperlipidemia | Contributes to the same atherosclerotic process driving arteriovenous compression |
| Hypercoagulable states | More relevant in RVO presenting at a younger age without the usual vascular risk profile |
| Age over 50 | Incidence rises steadily with age, paralleling the rise in vascular risk factors |
None of these factors is unique to the eye, which is the point: an RVO diagnosis is as much a signal about systemic vascular health as it is a retinal event, and management appropriately includes addressing blood pressure and metabolic risk alongside whatever intraocular treatment the macular edema or ischemia requires.
Section 06 — The Complication That Changes Everything
When ischemia
turns into
neovascular glaucoma.
The complication that makes ischemic CRVO an emergency rather than a routine follow-up is neovascular glaucoma. It is the reason ischemic and non-ischemic classification is not academic — it is the variable that decides how closely an eye needs to be watched in the months after diagnosis.
A large area of ischemic retina releases vascular endothelial growth factor (VEGF) as a response to oxygen starvation. In most tissues that drives helpful new blood vessel growth; in the eye, when those signals reach the iris and the anterior chamber angle, they trigger fragile, abnormal vessels (rubeosis iridis) that can physically block the eye's normal fluid drainage pathway. The result is a rapid, often severe rise in intraocular pressure that is difficult to control with drops alone — historically nicknamed "90-day glaucoma" because it classically appeared within about three months of an ischemic CRVO, though it can occur earlier or later.
Section 07 — Where the Decision Actually Gets Made
Same symptom,
different urgency —
an illustrative comparison.
Two patients can describe the same complaint — sudden, painless blurring in one eye — and be on entirely different clinical tracks once the fundus exam and angiography sort out which type of occlusion, and which ischemic status, they actually have.
A composite BRVO presentation: painless blurring affecting the upper or lower half of vision in one eye, corresponding to hemorrhage and edema along one branch vein, often at a visible arteriovenous crossing on exam. Visual acuity may be only mildly reduced if the occlusion spares the fovea. Management centers on monitoring, treating macular edema if it involves the center of vision, and addressing systemic risk factors — the prognosis for at least partial visual recovery is generally favorable.
A composite ischemic CRVO presentation: sudden, more uniform, and often more severe blurring across the entire visual field of one eye, with diffuse hemorrhage in all four quadrants of the retina on exam (the classic "blood and thunder" fundus appearance) and a relative afferent pupillary defect suggesting significant ischemia. This eye needs angiography to confirm ischemic status and a short-interval follow-up schedule specifically to watch for anterior segment neovascularization, independent of whatever happens with the macular edema itself.
The point is not that one occlusion is "worse" as a category — both merit prompt ophthalmic evaluation for any sudden visual change — but that the same first symptom can sit on either a watchful, largely reassuring path or an urgent, closely monitored one, and the fundus exam plus angiography is what tells them apart, not the symptom alone.
Section 08 — FAQ
Frequently asked questions
about retinal vein occlusion.
Retinal vein occlusion (RVO) is a blockage, usually a thrombus, forming in one of the veins that drain blood out of the retina. Blood keeps arriving through the retinal arteries but cannot leave normally, so pressure builds up behind the blockage, veins become engorged and tortuous, and the retina develops hemorrhages, swelling and, in more severe cases, areas starved of blood flow. It is the second most common retinal vascular disease after diabetic retinopathy.
The difference is where the blockage sits. Branch retinal vein occlusion (BRVO) blocks one of the smaller branch veins, typically at a point where it crosses under a stiffer retinal artery, so only the section of retina that branch drains is affected. Central retinal vein occlusion (CRVO) blocks the single central retinal vein at or near the optic nerve, at the narrow scleral canal called the lamina cribrosa, affecting the entire retina at once. BRVO is reported to occur roughly four times more often than CRVO in population-based studies, and CRVO is generally the more visually threatening of the two because it involves the whole retina rather than one sector.
In BRVO, the vein and an overlying artery share a common connective-tissue sheath at crossing points; a thickened, more rigid artery (from atherosclerosis or chronic hypertension) can compress the vein at that shared sheath, disturbing blood flow enough to trigger clot formation. In CRVO, the mechanism is similar but occurs where the vein exits the eye through the lamina cribrosa alongside the central retinal artery, inside a shared, rigid scleral canal. The dominant systemic risk factors for both are hypertension, atherosclerotic disease, diabetes, and elevated intraocular pressure or glaucoma; age over 50 and hypercoagulable states also raise risk.
The leading cause of vision loss in both BRVO and CRVO is macular edema — fluid leaking into the central retina because the congested veins and damaged capillaries can no longer hold it in. Macular edema is treatable, most often with intravitreal anti-VEGF injections or a corticosteroid implant, both of which reduce leakage and can recover meaningful vision, though outcomes depend heavily on how much macular ischemia and how long the edema has been present before treatment starts.
When a large area of retina is starved of blood flow, as happens in ischemic CRVO, the retina releases VEGF signals that can trigger abnormal new blood vessels to grow on the iris and in the eye's drainage angle. These fragile vessels can block normal fluid outflow and cause a severe, often difficult-to-control form of glaucoma historically nicknamed "90-day glaucoma" for how soon after an ischemic CRVO it can appear. It is treated with panretinal laser photocoagulation to reduce the ischemic drive, anti-VEGF injections, and, if pressure remains uncontrolled, glaucoma surgery.
Intravitreal anti-VEGF injections (ranibizumab, aflibercept, and off-label bevacizumab) are now first-line for the macular edema of both BRVO and CRVO, supported by pivotal trials including BRAVO, CRUISE, GALILEO and COPERNICUS. An intravitreal corticosteroid implant is a well-evidenced alternative, particularly in eyes that respond poorly to anti-VEGF or are already pseudophakic, based on the GENEVA trial. Grid or focal laser, once the standard for BRVO macular edema under the Branch Vein Occlusion Study, is now mostly reserved for cases not resolving with injections. Panretinal photocoagulation remains the standard response once retinal or iris neovascularization develops.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Retinal Vein Occlusion: BRVO vs CRVO, Causes & Anti-VEGF Treatment (2026 Guide)